Cancer evolution: Darwin and beyond
Clinical and laboratory studies over recent decades have established branched evolution as
a feature of cancer. However, while grounded in somatic selection, several lines of evidence …
a feature of cancer. However, while grounded in somatic selection, several lines of evidence …
Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond
Cell-free DNA (cfDNA) derived from tumours is present in the plasma of cancer patients. The
majority of currently available studies on the use of this circulating tumour DNA (ctDNA) deal …
majority of currently available studies on the use of this circulating tumour DNA (ctDNA) deal …
[HTML][HTML] Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
EA Rozeman, EP Hoefsmit, ILM Reijers, RPM Saw… - Nature medicine, 2021 - nature.com
Neoadjuvant ipilimumab plus nivolumab showed high pathologic response rates (pRRs) in
patients with macroscopic stage III melanoma in the phase 1b OpACIN (NCT02437279) and …
patients with macroscopic stage III melanoma in the phase 1b OpACIN (NCT02437279) and …
[HTML][HTML] Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells
Single-cell technologies have contributed to unravelling tumour heterogeneity, now
considered a hallmark of cancer and one of the main causes of tumour resistance to cancer …
considered a hallmark of cancer and one of the main causes of tumour resistance to cancer …
[HTML][HTML] Practical recommendations for using ctDNA in clinical decision making
SA Cohen, MC Liu, A Aleshin - Nature, 2023 - nature.com
The continuous improvement in cancer care over the past decade has led to a gradual
decrease in cancer-related deaths. This is largely attributed to improved treatment and …
decrease in cancer-related deaths. This is largely attributed to improved treatment and …
[HTML][HTML] Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium …
AM Menzies, RN Amaria, EA Rozeman, AC Huang… - Nature medicine, 2021 - nature.com
The association among pathological response, recurrence-free survival (RFS) and overall
survival (OS) with neoadjuvant therapy in melanoma remains unclear. In this study, we …
survival (OS) with neoadjuvant therapy in melanoma remains unclear. In this study, we …
Current and future clinical applications of ctDNA in immuno-oncology
JC Stadler, Y Belloum, B Deitert, M Sementsov… - Cancer Research, 2022 - AACR
Testing peripheral blood for circulating tumor DNA (ctDNA) offers a minimally invasive
opportunity to diagnose, characterize, and monitor the disease in individual cancer patients …
opportunity to diagnose, characterize, and monitor the disease in individual cancer patients …
Prognostic significance of blood-based multi-cancer detection in plasma cell-free DNA
Purpose: We recently reported the development of a cell-free DNA (cfDNA) targeted
methylation (TM)-based sequencing approach for a multi-cancer early detection (MCED) test …
methylation (TM)-based sequencing approach for a multi-cancer early detection (MCED) test …
Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)—a personalised circulating tumour DNA analysis in …
S Flach, K Howarth, S Hackinger, C Pipinikas… - British Journal of …, 2022 - nature.com
Background Head and neck squamous cell carcinoma (HNSCC) remain a substantial
burden to global health. Cell-free circulating tumour DNA (ctDNA) is an emerging biomarker …
burden to global health. Cell-free circulating tumour DNA (ctDNA) is an emerging biomarker …
The promise of neoadjuvant immunotherapy and surgery for cancer treatment
Cancer immunotherapies utilizing immune checkpoint inhibitors (ICI) have demonstrated
durable efficacy in a proportion of patients with advanced/metastatic cancers. More recently …
durable efficacy in a proportion of patients with advanced/metastatic cancers. More recently …